膜性肾病的研究进展
Advances in the Research of Membranous Nephropathy
DOI: 10.12677/ACM.2024.142602, PDF,   
作者: 张惠紫, 苏 华*:华中科技大学同济医学院附属协和医院肾内科,湖北 武汉
关键词: 膜性肾病靶抗原病理特征治疗Membranous Nephropathy Target Antigen Pathological Features Treatment
摘要: 膜性肾病(membranous nephropathy, MN)是具有共同的组织病理学模式的一种异质性疾病,常表现为肾病综合征(nephrotic syndrome, NS),是成人NS最常见的原因。MN的病因多样,其发病机制尚未完全阐明,但多认为与足细胞损伤有关,靶抗原的发现为其发病机制、诊断和治疗提供了新的方向。本文总结了MN的病因、分类、靶抗原,讨论其发病机制、病理特征等,以期为MN的早期诊断及治疗提供新的见解。
Abstract: Membranous nephropathy (MN) manifests as a heterogeneous disease sharing a common histo-pathological pattern, frequently presenting as Nephrotic syndrome (NS), and stands as the pre-dominant cause of NS among adults. The etiology of MN exhibits considerable diversity, and its pathogenesis remains incompletely elucidated, albeit the prevailing belief in its association with podocyte injury. Notably, the identification of target antigens has introduced novel dimensions to the understanding of MN’s pathogenesis, diagnosis, and therapeutic strategies. This article endeav-ors to comprehensively delineate the etiological spectrum, classification intricacies, and pertinent target antigens characterizing MN. Furthermore, it delves into the nuanced exploration of its path-ogenesis and pathological attributes, thereby aiming to furnish novel perspectives conducive to the advancement of early diagnostic modalities and therapeutic interventions for MN.
文章引用:张惠紫, 苏华. 膜性肾病的研究进展[J]. 临床医学进展, 2024, 14(2): 4352-4358. https://doi.org/10.12677/ACM.2024.142602

参考文献

[1] Zabala Ramirez, M.J., Stein, E.J. and Jain, K. (2023) Nephrotic Syndrome for the Internist. Medical Clinics of North America, 107, 727-737. [Google Scholar] [CrossRef] [PubMed]
[2] Ronco, P. and Debiec, H. (2017) A Po-docyte View of Membranous Nephropathy: From Heymann Nephritis to the Childhood Human Disease. Pflügers Ar-chiv—European Journal of Physiology, 469, 997-1005. [Google Scholar] [CrossRef] [PubMed]
[3] Dantas, M., Silva, L.B.B., Pontes, B.T.M., et al. (2023) Mem-branous Nephropathy. Brazilian Journal of Nephrology, 45, 229-243. [Google Scholar] [CrossRef
[4] Ronco, P. and Debiec, H. (2015) Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Patient’s Care. Lancet, 385, 1983-1992. [Google Scholar] [CrossRef
[5] Starzynska-Kubicka, A., Perkowska-Ptasinska, A. and Gor-nicka, B. (2018) Membranous Glomerulonephritis—A Common, Unspecific Pattern of Glomerular Injury. Polish Jour-nal of Pathology, 69, 209-218. [Google Scholar] [CrossRef] [PubMed]
[6] Polanco, N., Gutiérrez, E., Covarsí, A., et al. (2010) Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. Journal of the American Society of Neph-rology, 21, 697-704. [Google Scholar] [CrossRef
[7] MacTier, R., Boulton Jones, J.M., Payton, C.D., et al. (1986) The Natural History of Membranous Nephropathy in the West of Scotland. Quarterly Journal of Medicine, 60, 793-802.
[8] Cattran, D.C., Kim, E.D., Reich, H., et al. (2017) Membranous Nephropathy: Quantifying Remission Duration on Outcome. Journal of the American Society of Nephrology, 28, 995-1003. [Google Scholar] [CrossRef
[9] Glassock, R.J. (2021) Membranous Nephropathy: Classification Redux? Mayo Clinic Proceedings, 96, 523-525. [Google Scholar] [CrossRef] [PubMed]
[10] Alsharhan, L. and Beck Jr., L.H. (2021) Membranous Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 77, 440-453. [Google Scholar] [CrossRef] [PubMed]
[11] Safar-Boueri, L., Piya, A., Beck Jr., L.H., et al. (2021) Membra-nous Nephropathy: Diagnosis, Treatment, and Monitoring in the Post-PLA2R Era. Pediatric Nephrology, 36, 19-30. [Google Scholar] [CrossRef] [PubMed]
[12] Pozdzik, A., Touzani, F., Brocheriou, I. and Corazza, F. (2019) Molecular Classification of Membranous Nephropathy. Current Opinion in Nephrology and Hypertension, 28, 336-344. [Google Scholar] [CrossRef
[13] Adler, S.G., Wang, H., Ward, H.J., et al. (1983) Electrical Charge. It’s Role in the Pathogenesis and Prevention of Experimental Membranous Nephropathy in the Rabbit. Journal of Clinical Investigation, 71, 487-499. [Google Scholar] [CrossRef
[14] Debiec, H., Guigonis, V., Mougenot, B., et al. (2002) Antenatal Membra-nous Glomerulonephritis Due to Anti-Neutral Endopeptidase Antibodies. The New England Journal of Medicine, 346, 2053-2060. [Google Scholar] [CrossRef
[15] Beck Jr., L.H., Bonegio, R.G., Lambeau, G., et al. (2009) M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. The New England Journal of Medicine, 361, 11-21. [Google Scholar] [CrossRef
[16] Tomas, N.M., Beck Jr., L.H., Meyer-Schwesinger, C., et al. (2014) Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. The New England Journal of Medicine, 371, 2277-2287. [Google Scholar] [CrossRef
[17] Sethi, S. and Fervenza, F.C. (2023) Membranous Nephropa-thy-Diagnosis and Identification of Target Antigens. Nephrology Dialysis Transplantation. [Google Scholar] [CrossRef] [PubMed]
[18] Sethi, S., Madden, B.J., Debiec, H., et al. (2019) Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. Journal of the American Society of Nephrology, 30, 1123-1136. [Google Scholar] [CrossRef
[19] Sethi, S., Debiec, H., Madden, B., et al. (2020) Neural Epidermal Growth Factor-Like 1 Protein (NELL-1) Associated Membranous Nephropathy. Kidney International, 97, 163-174. [Google Scholar] [CrossRef] [PubMed]
[20] Caza, T.N., Hassen, S.I., Kuperman, M., et al. (2021) Neural Cell Adhesion Molecule 1 Is a Novel Autoantigen in Membranous Lupus Nephritis. Kidney International, 100, 171-181. [Google Scholar] [CrossRef] [PubMed]
[21] Sethi, S., Debiec, H., Madden, B., et al. (2020) Semaphorin 3B-Associated Membranous Nephropathy Is a Distinct Type of Disease Predominantly Present in Pediatric Patients. Kidney International, 98, 1253-1264. [Google Scholar] [CrossRef] [PubMed]
[22] Sethi, S., Madden, B., Debiec, H., et al. (2021) Protocadherin 7-Associated Membranous Nephropathy. Journal of the American Society of Nephrology, 32, 1249-1261. [Google Scholar] [CrossRef
[23] Al-Rabadi, L.F., Caza, T., Trivin-Avillach, C., et al. (2021) Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 32, 1666-1681. [Google Scholar] [CrossRef
[24] Reinhard, L., Machalitza, M., Wiech, T., et al. (2022) Netrin G1 Is a Novel Target Antigen in Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 33, 1823-1831. [Google Scholar] [CrossRef
[25] Caza, T.N., Hassen, S.I., Kenan, D.J., et al. (2021) Transforming Growth Factor β Receptor 3 (TGFBR3)-Associated Membranous Nephropathy. Kidney 360, 2, 1275-1286. [Google Scholar] [CrossRef
[26] Le Quintrec, M., Teisseyre, M., Bec, N., et al. (2021) Contactin-1 Is a Novel Target Antigen in Membranous Nephropathy Associated with Chronic Inflammatory Demyelinating Polyneu-ropathy. Kidney International, 100, 1240-1249. [Google Scholar] [CrossRef] [PubMed]
[27] Sethi, S., Madden, B., Casal Moura, M., et al. (2022) Hematopoiet-ic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology, 33, 1033-1044. [Google Scholar] [CrossRef
[28] Sethi, S., Madden, B., Casal Moura, M., et al. (2023) Membranous Nephropathy in Syphilis Is Associated with Neuron-Derived Neurotrophic Factor. Journal of the American Society of Nephrology, 34, 374-384. [Google Scholar] [CrossRef
[29] Caza, T.N., Storey, A., Hassen, S.I., et al. (2023) Discovery of Seven Novel Putative Antigens in Membranous Nephropathy and Membranous Lupus Nephritis Identified By Mass Spectrometry. Kidney International, 103, 593-606. [Google Scholar] [CrossRef] [PubMed]
[30] Burbelo, P.D., Joshi, M., Chaturvedi, A., et al. (2020) Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. Journal of the American Society of Neph-rology, 31, 208-217. [Google Scholar] [CrossRef
[31] Kistler, A.D. and Salant, D.J. (2023) Complement Activation and Effector Pathways in Membranous Nephropathy. Kidney International, 105, 473-483. [Google Scholar] [CrossRef] [PubMed]
[32] Liu, W., Huang, G., Rui, H., et al. (2022) Course Monitoring of Membranous Nephropathy: Both Autoantibodies and Podocytes Require Multidimensional Attention. Autoimmunity Re-views, 21, Article ID: 102976. [Google Scholar] [CrossRef] [PubMed]
[33] Yang, L., Wu, Y., Lin, S., et al. (2021) SPLA2-IB and PLA2R Mediate Insufficient Autophagy and Contribute to Podocyte Injury in Idiopathic Membranous Nephropathy by Activation of the P38MAPK/MTOR/ULK1 (Ser757) Signaling Pathway. FASEB Journal, 35, e21170. [Google Scholar] [CrossRef
[34] Chen, W., Lin, X., Huang, J., et al. (2014) Integrated Profiling of Mi-croRNA Expression in Membranous Nephropathy Using High-Throughput Sequencing Technology. International Journal of Molecular Medicine, 33, 25-34. [Google Scholar] [CrossRef] [PubMed]
[35] He, W., Zhang, J., Yuan, S., et al. (2021) Integrative Analysis of MiRNA-MRNA Network in Idiopathic Membranous Nephropathy by Bioinformatics Analysis. PeerJ, 9, e12271. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, D., Liu, F., Wang, X., et al. (2018) MiR-130a-5p Prevents Angioten-sin II-Induced Podocyte Apoptosis by Modulating M-Type Phospholipase A2 Receptor. Cell Cycle, 17, 2484-2495. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, Q., Bin, S., Budge, K.L., et al. (2024) C3aR-Initiated Signaling Is a Critical Mechanism of Podocyte Injury in Membranous Nephropathy. JCI Insight, 9, e172976. [Google Scholar] [CrossRef] [PubMed]
[38] Nangaku, M., Shankland, S.J. and Couser, W.G. (2005) Cellular Response to Injury in Membranous Nephropathy. Journal of the American Society of Nephrology, 16, 1195-204. [Google Scholar] [CrossRef
[39] Cunningham, P.N. and Quigg, R.J. (2005) Contrasting Roles of Complement Activation and Its Regulation in Membranous Nephropathy. Journal of the American Society of Nephrology, 16, 1214-1222. [Google Scholar] [CrossRef
[40] Lerner, G.B., Virmani, S., Henderson, J.M., et al. (2021) A Con-ceptual Framework Linking Immunology, Pathology, and Clinical Features in Primary Membranous Nephropathy. Kid-ney International, 100, 289-300. [Google Scholar] [CrossRef] [PubMed]
[41] Cai, Q. and Hendricks, A.R. (2020) Membranous Nephropathy: A Ten-Year Journey of Discoveries. Seminars in Diagnostic Pathology, 37, 116-120. [Google Scholar] [CrossRef] [PubMed]
[42] Tesar, V. and Hruskova, Z. (2021) Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. Frontiers in Immunology, 12, Article 593288. [Google Scholar] [CrossRef] [PubMed]
[43] Kidney Disease: Improving Global Outcomes (KDIGO) Glomer-ular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276. [Google Scholar] [CrossRef] [PubMed]
[44] Ronco, P., Beck, L., Debiec, H., et al. (2021) Membranous Nephropathy. Nature Reviews Disease Primers, 7, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[45] Sexton, D.J., De Freitas, D.G., Little, M.A., et al. (2018) Di-rect-Acting Oral Anticoagulants as Prophylaxis against Thromboembolism in the Nephrotic Syndrome. Kidney Interna-tional Reports, 3, 784-793. [Google Scholar] [CrossRef] [PubMed]
[46] Raza, A. and Aggarwal, S. (2021) Membranous Glomerulonephritis. StatPearls, Treasure Island.
[47] Fernandez-Juarez, G., Rojas-Rivera, J., Logt, A.V., et al. (2021) The STARMEN Trial Indicates That Alternating Treatment with Corticosteroids and Cyclophosphamide Is Superior to Sequential Treatment with Tacrolimus and Rituximab in Primary Membranous Nephropathy. Kidney International, 99, 986-998. [Google Scholar] [CrossRef] [PubMed]
[48] Ronco, P., Plaisier, E. and Debiec, H. (2021) Advances in Mem-branous Nephropathy. Journal of Clinical Medicine, 10, Article 607. [Google Scholar] [CrossRef] [PubMed]